Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Oct 03, 2018 3:40pm
155 Views
Post# 28739957

RE:RE:RE:RE:RE:RE:RE:Tomorrow

RE:RE:RE:RE:RE:RE:RE:Tomorrow
Balsbuster wrote: My limited understanding is tht J codes are issued annually.  Thery are necessary for the most efficient and expedieted reimbursment of drug expense by the doctor.  Without a J code the request from medicare is more manual (outside the standard system) and the reimbursment turnaround is slower.  While drugs can be approved antime during the year, J codes are only issed I assume  starting Jan 1.  They can issue a Q code in the interim first year, which is similar to a J code, but not quite as utilized by doctors.  J codes are just another reason most drugs get out of the gate slowly.  Especially if the goverment is your primary source of revenue.  Commercial payers are not impacted by this.  


A quick Google search suggests that J3590 (unclassified biologic) is being used until it gets its own code.

Bullboard Posts